It was my understanding that they did this split in this way to allow holders of ZENE to benefit from a possible sale directly, but that any royalties that may come from any RVX or Zenith holdings will be at the companies discretion to distribute.  Prior to this, any royalties derived from either RVX or Zenith epigenetics were held in a single company, precluding in ways a sale of the bio end of Zenith.